Clinical trial data in support of changing guidelines in osteoarthritis treatment

Journal of Pain Research

Volumn 7, Issue , 2014, Pages 211-218

  Balmaceda, Casilda M ^a  

^a New York Otology   (United States)

Author keywords

Chronic pain; Diclofenac; Osteoarthritis; Practice guidelines; Topical NSAIDs

Indexed keywords

DICLOFENAC; DICLOFENAC EPOLAMINE; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ABDOMINAL PAIN; ANALGESIA; ANEMIA; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; GASTRITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HALITOSIS; HEADACHE; HUMAN; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KNEE OSTEOARTHRITIS; LIVER DYSFUNCTION; MEDICAL SOCIETY; MICROEMULSION; NAUSEA; NONHUMAN; NOTE; OSTEOARTHRITIS; PRACTICE GUIDELINE; PROSTAGLANDIN SYNTHESIS; RASH; RESPIRATORY TRACT DISEASE; RISK FACTOR; TREATMENT DURATION; VERTIGO;

EID: 84898925290     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S45321     Document Type: Note

References (74)

1. Lawrence RC, Felson DT, Helmick CG, et al; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008; 58(1): 26-35.
2. Murphy L, Schwartz TA, Helmick CG, et al. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum. 2008; 59(9): 1207-1213.
3. Guccione AA, Felson DT, Anderson JJ, et al. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Pub Health. 1994; 84(3): 351-358.
4. Christensen R, Bartels EM, Astrup A, Bliddal H. Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2007; 66(4): 433-439.
5. Batterham SI, Heywood S, Keating JL. Systematic review and meta-analysis comparing land and aquatic exercise for people with hip or knee arthritis on function, mobility and other health outcomes. BMC Musculoskelet Disord. 2011; 12: 123.
6. Deyle GD, Henderson NE, Matekel RL, Ryder MG, Garber MB, Allison SC. Effectiveness of manual physical therapy and exercise in osteoarthritis of the knee. A randomized, controlled trial. Ann Intern Med. 2000; 132(3): 173-181.
7. Pisters MF, Veenhof C, Schellevis FG, De Bakker DG, Dekker J. Long-term effectiveness of exercise therapy in patients with osteoarthritis of the hip or knee: a randomized controlled trial comparing two different physical therapy interventions. Osteoarthritis Cartilage. 2010; 18(8): 1019-1026.
8. Barkin RL, Beckerman M, Blum SL, Clark FM, Koh EK, Wu DS. Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult? Drugs Aging. 2010; 27(10): 775-789.
9. Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA. 2006; 296(1): 87-93.
10. Raffa RB. Pharmacology of oral combination analgesics: rational therapy for pain. J Clin Pharm Ther. 2001; 26(4): 257-264.
11. Doherty M, Hawkey C, Goulder M, et al. A randomised controlled trial of ibuprofen, paracetamol or a combination tablet of ibuprofen/paracetamol in community-derived people with knee pain. Ann Rheum Dis. 2011; 70(9): 1534-1541.
12. Pareek A, Chandurkar N, Ambade R, Chandanvale A, Bartakke G. Efficacy and safety of etodolac-paracetamol fixed dose combination in patients with knee osteoarthritis flare-up: a randomized, double-blind comparative evaluation. Clin J Pain. 2010; 26(7): 561-566.
13. Pareek A, Chandurkar N, Sharma VD, Desai M, Kini S, Bartakke G. A randomized, multicentric, comparative evaluation of aceclofenac-paracetamol combination with aceclofenac alone in Indian patients with osteoarthritis flare-up. Expert Opin Pharmacother. 2009; 10(5): 727-735.
14. Fosbøl EL, Folke F, Jacobsen S, et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes. 2010; 3(4): 395-405.
15. Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011; 123(20): 2226-2235.
16. Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol. 2005; 45(8): 1295-1301.
17. Gengo FM, Rubin L, Robson M, et al. Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. J Clin Pharmacol. 2008; 48(1): 117-122.
18. Cheetham TC, Levy G, Niu F, Bixler F. Gastrointestinal safety of nonsteroidal antiinflammatory drugs and selective cyclooxygenase-2 inhibitors in patients on warfarin. Ann Pharmacother. 2009; 43(11): 1765-1773.
19. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999; 106(5B): 13S-24S.
20. Barkin RL, Buvanendran A. Focus on the COX-1 and COX-2 agents: renal events of nonsteroidal and anti-inflammatory drugs-NSAIDs. Am J Ther. 2004; 11(2): 124-129.
21. Richy F, Bruyere O, Ethgen O, et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis. 2004; 63(7): 759-766.
22. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005; 330(7504): 1366.
23. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005; 331(7528): 1310-1316.
24. Huerta C, Castellsague J, Varas-Lorenzo C, Rodríguez LA. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis. 2005; 45(3): 531-539.
25. Motsko SP, Rascati KL, Busti AJ, et al. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Drug Saf. 2006; 29(7): 621-632.
26. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA; American Heart Association. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007; 115(12): 1634-1642.
27. Boers M, Tangelder MJ, van Ingen H, Fort JG, Goldstein JL. The rate of NSAID-induced endoscopic ulcers increases linearly but not exponentially with age: a pooled analysis of 12 randomised trials. Ann Rheum Dis. 2007; 66(3): 417-418.
28. Franceschi M, Di Mario F, Leandro G, Maggi S. Pilotto A. Acid-related disorders in the elderly. Best Pract Res Clin Gastroenterol. 2009; 23(6): 839-848.
29. Lanas A, Tornero J, Zamorano JL. Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. Ann Rheum Dis. 2010; 69(8): 1453-1458.
30. Chan FK. Primer: managing NSAID-induced ulcer complications-balancing gastrointestinal and cardiovascular risks. Nat Clin Pract Gastroenterol Hepatol. 2006; 3(10): 563-573.
31. Zhang W, Doherty M, Leeb BF, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007; 66(3): 377-388.
32. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008; 16(2): 137-162.
33. Kneer W, Rother I, Rother M, Seidel E; IDEA-033-III-01 Study Group. A multiple-dose, open-label, safety, compliance, and usage evaluation study of epicutaneously applied Diractin (ketoprofen in Transfersome) in joint/musculoskeletal pain or soft tissue inflammation. Curr Drug Saf. 2009; 4(1): 5-10.
34. Wiechers JW. The barrier function of the skin in relation to percutaneous absorption of drugs. Pharm Weekbl Sci. 1989; 11(6): 185-198.
35. Komatsu T, Sakurada T. Comparison of the efficacy and skin permeability of topical NSAID preparations used in Europe. Eur J Pharm Sci. 2012; 47(5): 890-895.
36. Barkin RL. Topical Nonsteroidal Anti-Inflammatory Drugs: The Importance of Drug, Delivery, and Therapeutic Outcome. Am J Ther. Epub February 22, 2012.
37. Sarigüllü Ozgüney I, Yeşim Karasulu H, Kantarci G, Sözer S, Güneri T, Ertan G. Transdermal delivery of diclofenac sodium through rat skin from various formulations. AAPS PharmSciTech. 2006; 7(4): 88.
38. Haroutiunian S, Drennan D, Lipman A. Topical NSAID therapy for musculoskeletal pain. Pain Med. 2010; 11(4): 535-549.
39. Banning M. Topical diclofenac: clinical effectiveness and current uses in osteoarthritis of the knee and soft tissue injuries. Expert Opin Pharmacother. 2008; 9(16): 2921-2929.
40. Kienzler JL, Gold M, Nollevaux F. Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol. 2010; 50(1): 50-61.
41. Brunner M, Dehghanyar P, Seigfried B, Martin W, Menke G, Müller M. Favourable dermal penetration of diclofenac after administration to the skin using a novel spray gel formulation. Br J Clin Pharmacol. 2005; 60(5): 573-577.
42. Massey T, Derry S, Moore RA, McQuay HJ. Topical NSAIDs for acute pain in adults. Cochrane Database Syst Rev. 2010; (6): CD007402.
43. Dray A. Inflammatory mediators of pain. Br J Anaesth. 1995; 75(2): 125-131.
44. Heyneman CA, Lawless-Liday C, Wall GC. Oral versus topical NSAIDs in rheumatic diseases: a comparison. Drugs. 2000; 60(3): 555-574.
45. Castelnuovo E, Cross P, Mt-Isa S, Spencer A, Underwood M; TOIB study team. Cost-effectiveness of advising the use of topical or oral ibuprofen for knee pain; the TOIB study [ISRCTN: 79353052]. Rheumatology (Oxford). 2008; 47(7): 1077-1081.
46. Mason L, Moore RA, Edwards JE, Derry S, McQuay HJ. Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis. BMC Musculoskeletal Disord. 2004; 5: 28.
47. Galer BS, Rowbotham M, Perander J, Devers A, Friedman E. Topical diclofenac patch relieves minor sports injury pain: results of a multicenter controlled clinical trial. J Pain Symptom Manage. 2000; 19(4): 287-294.
48. Voltaren® Gel (diclofenac sodium topical gel) 1% [package insert]. Chadds Ford, PA: Endo Pharmaceuticals Inc.; 2009.
49. PENNSAID® (diclofenac sodium topical solution) 1. 5% w/w [package insert]. Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals, Inc; 2010.
50. Flector® Patch (diclofenac epolamine patch) 1. 3% [package insert]. Bristol, TN: King Pharmaceuticals Inc; 2011.
51. Herndon CM. Topical delivery of nonsteroidal anti-inflammatory drugs for osteoarthritis. J Pain Palliat Care Pharmacother. 2012; 26(1): 18-23.
52. Lin J, Zhang W, Jones A, Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ. 2004; 329(7461): 324.
53. Barthel HR, Haselwood D, Longley S 3rd, Gold MS, Altman RD. Randomized controlled trial of diclofenac sodium gel in knee osteoarthritis. Semin Arthritis Rheum. 2009; 39(3): 203-212.
54. Roth SH, Shainhouse JZ. Efficacy and safety of a topical diclofenac solution (pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial. Arch Intern Med. 2004; 164(18): 2017-2023.
55. Brühlmann P, Michel BA. Topical diclofenac patch in patients with knee osteoarthritis: a randomized, double-blind, controlled clinical trial. Clin Exp Rheumatol. 2003; 21(2): 193-198.
56. Simon LS, Grierson LM, Naseer Z, Bookman AA, Zev Shainhouse J. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain. 2009; 143(3): 238-245.
57. Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol. 2004; 31(10): 2002-2012.
58. Derry S, Moore RA, Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2012; 9: CD007400.
59. Makris UE, Kohler MJ, Fraenkel L. Adverse effects of topical nonsteroidal antiinflammatory drugs in older adults with osteoarthritis: a systematic literature review. J Rheumatol. 2010; 37(6): 1236-1243.
60. Zacher J, Altman R, Bellamy N, et al. Topical diclofenac and its role in pain and inflammation: an evidence-based review. Curr Med Res Opin. 2008; 24(4): 925-950.
61. Zacher J, Burger KJ, Färber L, Gräve M, Abberger H, Bertsch K. Topical diclofenac versus oral ibuprofen: a double blind, randomized clinical trial to demonstrate efficacy and tolerability in patients with activated osteoarthritis of the finger joints (Heberden and/or Bouchard Arthritis). Akt Rheumatol. 2001; 26(1): 7-14. German.
62. Baraf HS, Gold MS, Petruschke RA, Wieman MS. Tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities. Am J Geriatr Pharmacother. 2012; 10(1): 47-60.
63. Peniston JH, Gold MS, Wieman MS, Alwine LK. Long-term tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities. Clin Intervent Aging. 2012; 7: 517-523.
64. Roth SH, Fuller P. Diclofenac topical solution compared with oral diclofenac: a pooled safety analysis. J Pain Res. 2011; 4: 159-167.
65. Altman RD, Barthel HR. Topical therapies for osteoarthritis. Drugs. 2011; 71(10): 1259-1279.
66. Hochberg MC, Altman RD, April KT, et al; American College of Rheumatology. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012; 64(4): 465-474.
67. American Academy of Orthopaedic Surgeons (AAOS). Treatment of Osteoarthritis of the Knee: Evidence-Based Guideline. 2nd ed. Rosemont, IL: AAOS; 2013. Available from: http://www. aaos. org/oakcpg/. Accessed December 9, 2013.
68. National Institute for Health and Clinical Excellence (NICE). Osteoarthritis: the care and management of osteoarthritis in adults. NICE clinical guideline 59. London: NICE; 2008. Available from: http://www. nice. org. uk/nicemedia/pdf/cg59niceguideline. pdf. Accessed December 9, 2013.
69. Conaghan PG, Dickson J, Grant RL; Guideline Development Group. Care and management of osteoarthritis in adults: summary of NICE guidance. BMJ. 2008; 336(7642): 502-503.
70. Jordan KM, Arden NK, Doherty M, et al; Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003; 62(12): 1145-1155.
71. American Academy of Orthopaedic Surgeons. Treatment of Osteoarthritis of the Knee (Non-Arthroplasty). Rosemont, IL: American Academy of Orthopaedic Surgeons, 2008.
72. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009; 57(8): 1331-1346.
73. American Pain Society. Guideline for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis, and Juvenile Chronic Arthritis. 2nd ed. Glenview, IL: American Pain Society; 2002.
74. Manchikanti L, Boswell MV, Giordano J. Evidence-based interventional pain management: principles, problems, potential and applications. Pain Physician. 2007; 10(2): 329-356.